株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

モノクローナル抗体治療市場(がん、自己免疫疾患、感染性疾患、血液疾患、眼科疾患) - 世界産業の分析、規模、構成比、成長率、動向および予測

Monoclonal Antibody Therapeutics Market (Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Ophthalmological Diseases) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024

発行 Transparency Market Research 商品コード 428073
出版日 ページ情報 英文 185 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=113.97円で換算しております。
Back to Top
モノクローナル抗体治療市場(がん、自己免疫疾患、感染性疾患、血液疾患、眼科疾患) - 世界産業の分析、規模、構成比、成長率、動向および予測 Monoclonal Antibody Therapeutics Market (Cancer, Autoimmune Diseases, Infection, Hematological Diseases, Ophthalmological Diseases) - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024
出版日: 2017年01月12日 ページ情報: 英文 185 Pages
概要

当レポートでは、モノクローナル抗体治療の世界市場に注目し、今後の推移を適応症、抗体供給源、末端利用者および地域の別に予測するほか、産業構造、推進・抑制要因、機会、競合環境などの分析情報および主要企業のプロファイルをまとめています。

第1章 はじめに

  • 市場の定義と範囲
  • 市場セグメンテーション
  • 主要調査目的
  • 調査ハイライト

第2章 前提と調査方法

第3章 エグゼクティブサマリー - モノクローナル抗体治療の世界市場

第4章 市場概要

  • イントロダクション
    • 適応症の定義
    • 産業発展史
  • 概要
  • 重要市場指標
    • 地域・国別
    • 製品・適応症・末端利用者別
    • ターゲット市場別 - 世界的状況
  • 市場動態
    • 推進要因
    • 抑制要因
    • 機会分析
  • モノクローナル抗体治療世界市場の分析と予測
    • 市場収益予測(単位:100万ドル)
  • モノクローナル抗体治療市場 - 世界的需給状況
  • Porterのファイブフォース分析
  • バリューチェーン分析
  • 市場展望

第5章 モノクローナル抗体治療世界市場の分析と予測 - 適応症別

  • イントロダクションと定義
  • 重要所見・展開
  • 重要動向
  • 市場収益予測 - 適応症別
    • がん
    • 自己免疫疾患
    • 感染性疾患
    • 血液疾患
    • 眼科疾患
    • その他
  • 市場求心力 - 適応症別

第6章 モノクローナル抗体治療世界市場の分析と予測 - 抗体供給源別

  • イントロダクションと定義
  • 重要所見・展開
  • 重要動向
  • 市場収益予測 - 抗体供給源別
    • ヒト
    • ヒト化
    • キメラ
    • その他
  • 市場求心力 - 抗体供給源別

第7章 モノクローナル抗体治療世界市場の分析と予測 - 末端利用者別

  • イントロダクションと定義
  • 重要所見・展開
  • 重要動向
  • 市場収益予測 - 末端利用者別
    • 病院
    • 民間診療施設
    • 研究機関
  • 市場求心力 - 末端利用者別

第8章 モノクローナル抗体治療世界市場の分析と予測 - 地域別

  • 重要所見
  • 政策と規制
  • 市場収益予測 - 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中南米
    • 中東・アフリカ
  • 市場求心力 - 国・地域別

第9章 北米モノクローナル抗体治療市場の分析と予測

  • イントロダクション
    • 重要所見
    • 重要動向
  • 市場収益予測 - 適応症別
    • がん
    • 自己免疫疾患
    • 感染性疾患
    • 血液疾患
    • 眼科疾患
    • その他
  • 市場収益予測 - 抗体供給源別
    • ヒト
    • ヒト化
    • キメラ
    • その他
  • 市場収益予測 - 末端利用者別
    • 病院
    • 民間診療施設
    • 研究機関
  • 市場収益予測 - 国別
    • 米国
    • カナダ
  • 市場求心力分析
    • 適応症別
    • 抗体供給源別
    • 末端利用者別
    • 国別

第10章 欧州モノクローナル抗体治療市場の分析と予測

第11章 アジア太平洋地域モノクローナル抗体治療市場の分析と予測

第12章 中南米モノクローナル抗体治療市場の分析と予測

第13章 中東・アフリカモノクローナル抗体治療市場の分析と予測

第14章 競合環境

  • 市場参入企業 - 競合マトリクス(企業階層・規模別)
  • 市場シェア分析 - 企業別
  • 企業プロファイル
目次

Global Monoclonal Antibody Therapeutics Market: Snapshot

The biological therapy used for treating various kinds of severe and chronic conditions are known as monoclonal antibodies. These are applied in the treatment of serious conditions such as cancer, rheumatoid arthritis, Crohn's diseases, psoriasis, osteoporosis, systemic lupus erythematous and others. These are target only the affected areas to destroy the diseased cells, thus restoring the immune system. The research report by Transparency Market Research states that the global monoclonal antibody therapeutics market was worth US$86.7 bn in 2015 and is expected to reach US$245.8 bn by 2024. Between the forecast years of 2016 and 2024, the overall market is expected to rise at a CAGR of 12.6%.

The rising incidence of cancer across the globe is expected to drive the global market in the coming years. According to the World Health Organization, the world is expected to witness a rise of 70% in the number of cancer cases over the next few years. The statistics indicate that of these, 60% will be from Asia, Africa, and Latin America. The market is also likely to be favored by the growing approvals to research and develop new antibodies, especially across Europe and the U.S. Additionally, commercialization of these drugs will also contribute to the growing revenue of the global market.

image1

Autoimmune Diseases Showcase Steady Demand for Monoclonal Antibody Therapeutics

On the basis of application, the global monoclonal antibody therapeutics market is segmented into cancer, ophthalmological diseases, infection, autoimmune diseases, and hematological diseases among others. Of these, demand for treating autoimmune diseases with monoclonal antibody therapeutics is expected to remain at an all-time high in the coming years. The growing awareness about diseases, improving accessibility to healthcare, widening range of monoclonal antibody therapeutics, and huge investments in research and development of these therapeutics are expected to propel the segment in the coming years. Cancer is the second largest segment in the global market due to the high prevalence of the disease and an urgent need to treat the same.

North America to Remain Leading Segment due to Affordable Healthcare

In terms of geography, the global market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Analysts predict that the North America monoclonal antibody therapeutics market is likely to lead due to several reasons. Europe is expected to follow suit. As of 2015, the collective share of these two regions stood at 62.7% in the global market. The vast pool of geriatrics, well-established reimbursement policies, affordable healthcare, and growing awareness of diseases is expected to drive the market in North America in the coming few years. On the other hand, Europe monoclonal antibody therapeutics market is expected to thrive due to the increasing research and development in developing novel products.

Asia Pacific is also expected to show promise of a steady growth as the region has a huge population base with vast scope of unmet medical needs. The growing focus of governments in developing countries to improve the healthcare facilities is also expected to boost the demand for monoclonal antibody therapeutics in the coming years.

The key players operating in the global monoclonal antibody therapeutics market are GlaxoSmithKline Plc., Bayer AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., Sanofi, Merck & Co., Inc., AbbVie Inc., Novartis AG, Amgen Inc., Bristol - Myers Squibb Company, Johnson & Johnson, and Biogen Inc. among others. The players are expected to focus on strategic mergers and acquisitions in the coming years to improve their foothold in the global market.

Report Description

Global Monoclonal Antibody Therapeutics Market: Overview

Monoclonal antibodies are a type of biological therapy used in the treatment serious conditions such as cancer, rheumatoid arthritis, Crohn's diseases, psoriasis, osteoporosis, systemic lupus erythematous, and others. Monoclonal antibody are target specific in action by not affect the other cells of the body thus restores the immune system.

The market report comprises an elaborated executive summary, which includes market snapshot that provides information about various segments of the market. It also provides information and data analysis of the market with respect to market segments based on application, source, end-user, and geography. The market overview section of the report analyzes market dynamics such as drivers, restraints and opportunities that influences the monoclonal antibody therapeutics market in the current and future scenario.

Global Monoclonal Antibody Therapeutics Market: Segmentation

This report analyzes the current and future prospects of the monoclonal antibody therapeutics market based on type of application, source, end user and geography. By application monoclonal antibodies are segmented according to the therapeutic area such as cancer, autoimmune diseases, infection, hematological diseases, ophthalmological diseases and others which include monoclonal antibodies used in treating cardiovascular, respiratory, and orthopedic disorders as well as monoclonal antibodies used in the prevention of transplant rejection.

By source monoclonal antibodies are segmented into human, humanized, chimeric, and others, which include peptide body and murine antibodies. The human monoclonal antibody segment is expected to be highest contributing segment in the monoclonal antibody therapeutic market during the forecast period. Various factors such as patent expiry of block buster drugs, robust pipeline of monoclonal antibodies indicated in the treating various types of cancer and other disorders such as hematological, cardiovascular and orthopedic and upcoming biosimilars, define the market growth over the forecast period.

Global Monoclonal Antibody Therapeutics Market: Research Methodology

The research is a combination of primary and secondary research, conducted for understanding and arriving at trends, used to forecast the expected revenue of the major monoclonal antibody therapeutics market in the near future. Primary research formed the bulk of our research efforts with information collected from in-depth interviews and discussions with a number of key industry experts and opinion leaders. Secondary research involved study of company websites, annual reports, press releases, investor presentations, analyst presentation and various international and national databases.

The report provides estimated market size in terms of US$ Mn for each by application, source, end user, and geography for the period 2014 to 2024, considering the macro and micro environmental factors. The revenue generated from each product was calculated by considering number of products used in the procedures and their market demand as per their use, number of product launched, annual revenue generated by products of each sub segment, trends in industry, end user trend, and adoption rate across all the geographies.

Global Monoclonal Antibody Therapeutics Market: Regional Outlook

Market share analysis among the market players is analyzed to signify the contribution of these players in the market in terms of percentage share. All these factors will help the market players to decide about the business strategies and plans to strengthen their positions in the global market. Based on geography, the market has been analyzed for major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The study also covers detailed country analysis contributing majorly in the monoclonal antibody therapeutics market.

Key Players Mentioned in this Report are:

The report also profiles the major players in the market and provides various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in the monoclonal antibody therapeutics market are Bayer AG, F. Hoffmann-La Roche Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline Plc., Merck & Co., Inc., Novartis AG, AbbVie Inc., Amgen Inc., Johnson & Johnson, Bristol - Myers Squibb Company and Biogen Inc. .

The monoclonal antibody therapeutics market has been segmented as follows:

Monoclonal Antibody Therapeutics Market, by Application

  • Cancer
  • Autoimmune diseases
  • Infection
  • Hematological diseases
  • Ophthalmological diseases
  • Others

Monoclonal Antibody Therapeutics Market, by Source

  • Human
  • Humanized
  • Chimeric
  • Others

Monoclonal Antibody Therapeutics Market, by End Users

  • Hospitals
  • Private Clinics
  • Research Institute

Monoclonal Antibody Therapeutics Market, by Geography

  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Europe
    • U.K.
    • Germany
    • Spain
    • Italy
    • France
    • Rest of Europe
  • Asia Pacific
    • India
    • Japan
    • China
    • Australia
    • New Zealand
    • Rest of Asia Pacific
  • Middle East and Africa
    • South Africa
    • Saudi Arabia
    • A.E.
    • Rest of MEA

Table of Contents

1. Preface

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Monoclonal Antibody Therapeutics Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Application Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Key Market Indicators
    • 4.3.1. Region/Country Specific
    • 4.3.2. Product/Application/End Users Specific
    • 4.3.3. Target Market Specific - Global Scenario
  • 4.4. Market Dynamics
    • 4.4.1. Drivers
    • 4.4.2. Restraints
    • 4.4.3. Opportunity
  • 4.5. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, 2014-2024
    • 4.5.1. Market Revenue Projections (US$ Mn)
  • 4.6. Monoclonal Antibody Therapeutics Market - Global Supply Demand Scenario
  • 4.7. Porter's Five Force Analysis
  • 4.8. Value Chain Analysis
  • 4.9. Market Outlook

5. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By Application

  • 5.1. Introduction & Definition
  • 5.2. Key Findings / Developments
  • 5.3. Key Trends
  • 5.4. Market Value Forecast By Application , 2014-2024
    • 5.4.1. Cancer
    • 5.4.2. Autoimmune diseases
    • 5.4.3. Infection
    • 5.4.4. Hematological diseases
    • 5.4.5. Ophthalmological diseases
    • 5.4.6. Others
  • 5.5. Market Attractiveness By Application

6. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By Source

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Key Trends
  • 6.4. Market Value Forecast By Source , 2014-2024
    • 6.4.1. Human
    • 6.4.2. Humanized
    • 6.4.3. Chimeric
    • 6.4.4. Others
  • 6.5. Market Attractiveness By Source

7. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By End Users

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Key Trends
  • 7.4. Market Value Forecast By End Users , 2014-2024
    • 7.4.1. Hospital
    • 7.4.2. Private Clinic
    • 7.4.3. Research Institutes
  • 7.5. Market Attractiveness By End Users

8. Global Monoclonal Antibody Therapeutics Market Analysis and Forecasts, By Region

  • 8.1. Key Findings
  • 8.2. Policies and Regulations
  • 8.3. Market Value Forecast By Region
    • 8.3.1. North America
    • 8.3.2. Europe
    • 8.3.3. Asia Pacific
    • 8.3.4. Latin America
    • 8.3.5. Middle East & Africa
  • 8.4. Market Attractiveness By Country/Region

9. North America Monoclonal Antibody Therapeutics Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
    • 9.1.2. Key Trends
  • 9.2. Market Value Forecast By Application , 2014-2024
    • 9.2.1. Cancer
    • 9.2.2. Autoimmune diseases
    • 9.2.3. Infection
    • 9.2.4. Hematological diseases
    • 9.2.5. Ophthalmological diseases
    • 9.2.6. Others
  • 9.3. Market Value Forecast By Source , 2014-2024
    • 9.3.1. Human
    • 9.3.2. Humanized
    • 9.3.3. Chimeric
    • 9.3.4. Others
  • 9.4. Market Value Forecast By End Users , 2014-2024
    • 9.4.1. Hospital
    • 9.4.2. Private Clinic
    • 9.4.3. Research Institutes
  • 9.5. Market Value Forecast By Country , 2014-2024
    • 9.5.1. U.S.
    • 9.5.2. Canada
  • 9.6. Market Attractiveness Analysis
    • 9.6.1. By Application
    • 9.6.2. By Source
    • 9.6.3. By End Users
    • 9.6.4. By Country

10. Europe Monoclonal Antibody Therapeutics Market Analysis and Forecast

  • 10.1.Introduction
    • 10.1.1. Key Findings
    • 10.1.4. Key Trends
  • 10.2.Market Value Forecast By Application , 2014-2024
    • 10.2.1. Cancer
    • 10.2.2. Autoimmune diseases
    • 10.2.3. Infection
    • 10.2.4. Hematological diseases
    • 10.2.5. Ophthalmological diseases
    • 10.2.6. Others
  • 10.3.Market Value Forecast By Source , 2014-2024
    • 10.3.1. Human
    • 10.3.2. Humanized
    • 10.3.3. Chimeric
    • 10.3.4. Others
  • 10.4.Market Value Forecast By End Users , 2014-2024
    • 10.4.1. Hospital
    • 10.4.2. Private Clinic
    • 10.4.3. Research Institutes
  • 10.5.Market Value Forecast By Country , 2014-2024
    • 10.5.1. Germany
    • 10.5.2. U.K.
    • 10.5.3. France
    • 10.5.4. Spain
    • 10.5.5. Italy
    • 10.5.6. Rest of Europe
  • 10.6.Market Attractiveness Analysis
    • 10.6.1. By Application
    • 10.6.2. By Source
    • 10.6.3. By End Users
    • 10.6.4. By Country

11. Asia Pacific Monoclonal Antibody Therapeutics Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
    • 11.1.4. Key Trends
  • 11.2.Market Value Forecast By Application , 2014-2024
    • 11.2.1. Cancer
    • 11.2.2. Autoimmune diseases
    • 11.2.3. Infection
    • 11.2.4. Hematological diseases
    • 11.2.5. Ophthalmological diseases
    • 11.2.6. Others
  • 11.3.Market Value Forecast By Source , 2014-2024
    • 11.3.1. Human
    • 11.3.2. Humanized
    • 11.3.3. Chimeric
    • 11.3.4. Others
  • 11.4.Market Value Forecast By End Users , 2014-2024
    • 11.4.1. Hospital
    • 11.4.2. Private Clinic
    • 11.4.3. Research Institutes
  • 11.5.Market Value Forecast By Country , 2014-2024
    • 11.5.1. Japan
    • 11.5.2. China
    • 11.5.3. Australia
    • 11.5.4. New Zealand
    • 11.5.5. India
    • 11.5.6. Rest of Asia Pacific
  • 11.6.Market Attractiveness Analysis
    • 11.6.1. By Application
    • 11.6.2. By Source
    • 11.6.3. By End Users
    • 11.6.4. By Country

12. Latin America Monoclonal Antibody Therapeutics Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
    • 12.1.4. Key Trends
  • 12.2.Market Value Forecast By Application , 2014-2024
    • 12.2.1. Cancer
    • 12.2.2. Autoimmune diseases
    • 12.2.3. Infection
    • 12.2.4. Hematological diseases
    • 12.2.5. Ophthalmological diseases
    • 12.2.6. Others
  • 12.3.Market Value Forecast By Source , 2014-2024
    • 12.3.1. Human
    • 12.3.2. Humanized
    • 12.3.3. Chimeric
    • 12.3.4. Others
  • 12.4.Market Value Forecast By End Users , 2014-2024
    • 12.4.1. Hospital
    • 12.4.2. Private Clinic
    • 12.4.3. Research Institutes
  • 12.5.Market Value Forecast By Country , 2014-2024
    • 12.5.1. Brazil
    • 12.5.2. Mexico
    • 12.5.3. Rest of Latin America
  • 12.6.Market Attractiveness Analysis
    • 12.6.1. By Application
    • 12.6.2. By Source
    • 12.6.3. By End Users
    • 12.6.4. By Country

13. Middle East & Africa Monoclonal Antibody Therapeutics Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
    • 13.1.4. Key Trends
  • 13.2.Market Value Forecast By Application , 2014-2024
    • 13.2.1. Cancer
    • 13.2.2. Autoimmune diseases
    • 13.2.3. Infection
    • 13.2.4. Hematological diseases
    • 13.2.5. Ophthalmological diseases
    • 13.2.6. Others
  • 13.3.Market Value Forecast By Source , 2014-2024
    • 13.3.1. Human
    • 13.3.2. Humanized
    • 13.3.3. Chimeric
    • 13.3.4. Others
  • 13.4.Market Value Forecast By End Users , 2014-2024
    • 13.4.1. Hospital
    • 13.4.2. Private Clinic
    • 13.4.3. Research Institutes
  • 13.5.Market Value Forecast By Country , 2014-2024
    • 13.5.1. South Africa
    • 13.5.2. UAE
    • 13.5.3. Saudi Arabia
    • 13.5.4. Rest of Middle East and Africa
  • 13.6.Market Attractiveness Analysis
    • 13.6.1. By Application
    • 13.6.2. By Source
    • 13.6.3. By End Users
    • 13.6.4. By Country

14. Competition Landscape

  • 14.1.Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2.Market Share Analysis By Company (2015)
  • 14.3.Company Profiles (Details - Overview, Financials, Recent Developments, Strategy)
    • 14.3.1. Bayer AG
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Financial Overview
      • 14.3.1.3. Product Portfolio
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. F. Hoffmann-La Roche Ltd.
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Financial Overview
      • 14.3.2.3. Product Portfolio
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Pfizer, Inc.
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Financial Overview
      • 14.3.3.3. Product Portfolio
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Sanofi
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Financial Overview
      • 14.3.4.3. Product Portfolio
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. GlaxoSmithKline plc.
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Financial Overview
      • 14.3.5.3. Product Portfolio
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Merck & Co., Inc.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Financial Overview
      • 14.3.6.3. Product Portfolio
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Novartis AG
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Financial Overview
      • 14.3.7.3. Product Portfolio
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. AbbVie Inc.
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Financial Overview
      • 14.3.8.3. Product Portfolio
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. Amgen Inc.
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Financial Overview
      • 14.3.9.3. Product Portfolio
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Johnson & Johnson
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Financial Overview
      • 14.3.10.3. Product Portfolio
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview
    • 14.3.11. Bristol-Myers Squibb Company
      • 14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.11.2. Financial Overview
      • 14.3.11.3. Product Portfolio
      • 14.3.11.4. SWOT Analysis
      • 14.3.11.5. Strategic Overview
    • 14.3.12. Biogen Inc.
      • 14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.12.2. Financial Overview
      • 14.3.12.3. Product Portfolio
      • 14.3.12.4. SWOT Analysis
      • 14.3.12.5. Strategic Overview

List of Figures

  • Figure 1: Market Value Share By Application (2016) Revenue (US$ Mn)
  • Figure 2: Market Value Share By Source(2016) Revenue (US$ Mn)
  • Figure 3: Market Value Share By Application & Source (2016) Revenue (US$ Mn)
  • Figure 3: Market Value Share By End Users (2016) Revenue (US$ Mn)
  • Figure 4: Market Value Share By Region (2016) Revenue (US$ Mn)
  • Figure 3: Market Value Share By End Users & Region (2016) Revenue (US$ Mn)
  • Figure 5: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
  • Figure 6: Global Cancer Market Revenue (US$ Mn), 2014-2024
  • Figure 7: Global Autoimmune diseases Market Revenue (US$ Mn), 2014-2024
  • Figure 8: Global Infection Market Revenue (US$ Mn), 2014-2024
  • Figure 9: Global Hematological diseases Market Revenue (US$ Mn), 2014-2024
  • Figure 10: Global Ophthalmic diseases Market Revenue (US$ Mn), 2014-2024
  • Figure 11: Global Others Market Revenue (US$ Mn), 2014-2024
  • Figure 12: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Application, 2015
  • Figure 13: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
  • Figure 14: Global Human Market Revenue (US$ Mn), 2014-2024
  • Figure 15: Global Humanized Market Revenue (US$ Mn), 2014-2024
  • Figure 16: Global Chimeric Market Revenue (US$ Mn), 2014-2024
  • Figure 17: Global Others Market Revenue (US$ Mn), 2014-2024
  • Figure 18: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Source, 2015
  • Figure 19: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
  • Figure 20: Global Hospital Market Revenue (US$ Mn), 2014-2024
  • Figure 21: Global Private Clinics Market Revenue (US$ Mn), 2014-2024
  • Figure 22: Global Research Institutes Market Revenue (US$ Mn), 2014-2024
  • Figure 23: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By End Users, 2015
  • Figure 24: Global Monoclonal Antibody Therapeutics Market Value Share Analysis, by Region, 2015 and 2024
  • Figure 25: Global Monoclonal Antibody Therapeutics Market Attractiveness Analysis By Region, 2015
  • Figure 26: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015-2024
  • Figure 27: North America Monoclonal Antibody Y-o-Y Growth Projections, 2015-2024
  • Figure 28: North America Monoclonal Antibody Therapeutics Market Attractiveness By Country, 2014-2024
  • Figure 29: North America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
  • Figure 30: North America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
  • Figure 31: North America Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
  • Figure 32: North America Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
  • Figure 33: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
  • Figure 34: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
  • Figure 35: North America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, By End users, 2015
  • Figure 36 : Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015-2024
  • Figure 37: Europe Monoclonal Antibody Y-o-Y Growth Projections, 2015-2024
  • Figure 38: Europe Monoclonal Antibody Therapeutics Market Attractiveness By Country, 2014-2024
  • Figure 39: Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
  • Figure 40 : Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
  • Figure 41: Europe Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
  • Figure 42: Europe Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
  • Figure 43: Europe Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
  • Figure 44: Europe Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
  • Figure 45: Europe Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
  • Figure 46: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015-2024
  • Figure 47: Asia Pacific Monoclonal Antibody Y-o-Y Growth Projections, 2015-2024
  • Figure 48: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness By Country, 2014-2024
  • Figure 49: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
  • Figure 50: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
  • Figure 51: Asia Pacific Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
  • Figure 52: Asia Pacific Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
  • Figure 53: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
  • Figure 54: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
  • Figure 55: Asia Pacific Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
  • Figure 56: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015-2024
  • Figure 57: Latin America Monoclonal Antibody Y-o-Y Growth Projections, 2015-2024
  • Figure 58: Latin America Monoclonal Antibody Therapeutics Market Attractiveness By Country, 2014-2024
  • Figure 59: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
  • Figure 60: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
  • Figure 61: Latin America Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
  • Figure 62: Latin America Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
  • Figure 63: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
  • Figure 64: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
  • Figure 65: Latin America Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
  • Figure 66: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, 2015-2024
  • Figure 67: MEA Monoclonal Antibody Y-o-Y Growth Projections, 2015-2024
  • Figure 68: MEA Monoclonal Antibody Therapeutics Market Attractiveness By Country, 2014-2024
  • Figure 69: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by Application, 2015 and 2024
  • Figure 70: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by Source, 2015 and 2024
  • Figure 71: MEA Monoclonal Antibody Therapeutics Market Value Share Analysis, by End Users, 2015 and 2024
  • Figure 72: MEA Monoclonal Antibody Therapeutics Market by Country, 2015 and 2024
  • Figure 73: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Application, 2015
  • Figure 74: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by Source, 2015
  • Figure 75: MEA Monoclonal Antibody Therapeutics Market Attractiveness Analysis, by End Users, 2015
  • Figure 76: Global Monoclonal Antibody Therapeutics Market Share Analysis, by Company (2015)

List of Tables

  • Table 01: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 02: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 03: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by End Users, 2014-2024
  • Table 04: Global Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Region, 2014-2024
  • Table 05: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 06: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 07: North America Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014-2024
  • Table 08: North America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 09: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 10: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 11: Europe Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014-2024
  • Table 12: Europe Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 13: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 14: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 15: Asia Pacific Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014-2024
  • Table 16: Asia Pacific Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 17: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 18: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 19: Latin America Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014-2024
  • Table 20: Latin America Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014-2024
  • Table 21: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Application, 2014-2024
  • Table 22: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Source, 2014-2024
  • Table 23: MEA Monoclonal Antibody Therapeutics Market Forecast, by End Users, 2014-2024
  • Table 24: MEA Monoclonal Antibody Therapeutics Market Size (US$ Mn) Forecast, by Country, 2014-2024
Back to Top